Skip to main content

Table 2 Parotid gland overdose and replanning benefit assessments, based on the fraction or the cumulated doses, for all the 15 patients

From: Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia

 

D mean (Gy),mean (Min-max;SD)

p-value

 

Planned dose (1)

30.9 (9.2-54.6; 7.9)

-

Doses at the fraction

Without replanning (2)

33.0 (7.7-61.2; 9.9)

With replanning (3)

29.4 (4.1-51.7; 8.3)

PG overdose (4) = (2)-(1)

1.8 (−10.6-24.9; 5.8)

<0,001

Replanning benefit (5) = (3)-(2)

3.8 (0–23.8; 4.0)

<0,001

Cumulated doses

Without replanning (2)

32.0 (8.7-57.6; 9.3)

-

With replanning (3)

28.6 (4.6-51.2; 8.4)

PG Overdose (4) = (2)-(1)

1.1 (−7.9-10.0; 4.1)

0,1

Replanning benefit (5) = (3)-(2)

3.6 (0–12.2; 3.3)

<0,001

  1. PGs: parotid glands; Dmean: First, the mean PG dose was calculated for each patient and each week (DmeanWeekly). Then, the mean of the DMeanWeekly was calculated for each patient (DMeanPt). Finally, the mean of the DmeanPt was calculated for the whole population (D(mean)).
  2. p values are calculated using the Wilcoxon test, to test if the Dmean in (1) and (2), and if the Dmean in (2) and (3) are statistically different.